CYP26A1 and colorectal carcinoma: For instance, given that RA receptor-mutant CRC cells showed a similar response to CYP26A1 inhibitors (Liarozole and Talarozole) as non-mutant cells (Figure 6), this finding indicates that the inhibition of CYP26A1 leads to a high enough intracellular RA level to induce growth inhibition regardless of RA receptor genotype.